News & Events

Parkinson’s UK Announces Major Pharma Companies Sign Up to CPP

Major pharma companies sign up to groundbreaking Parkinson’s consortium Seven of the world’s largest pharmaceutical companies have signed up to a groundbreaking consortium aimed at accelerating the development of safe and effective therapies for Parkinson’s. The Critical Path for Parkinson’s consortium will bring together leading academics; industry members AbbVie, AstraZeneca, Biogen, Eli Lilly and Company, […]

C-Path’s Polycystic Kidney Disease Outcomes Consortium Secures EMA Qualification Opinion for Enrichment Biomarker in ADPKD

November 13, 2015 C-Path’s Polycystic Kidney Disease Outcomes Consortium Secures EMA Qualification Opinion for Enrichment Biomarker in ADPKD TUCSON, Ariz., November 13, 2015 – The Critical Path Institute (C-Path) announced today that the European Medicines Agency (EMA) rendered a positive qualification opinion to C-Path’s Polycystic Kidney Disease Outcomes Consortium (PKDOC) for total kidney volume (TKV) as a prognostic […]

Parkinson’s UK Receives CAMD Nonprofit Organization Award

Dr. Arthur Roach, Director of Research at Parkinson’s UK accepts the first Nonprofit Organization Award from CAMD presented by Dr. Diane Stephenson, Critical Path Institute, at the annual meeting held at FDA on Oct 20th, 2015. Parkinson’s UK is recognized for their leadership in supporting the launch of a fully dedicated consortium aimed at integrating […]

Parkinson’s UK and Critical Path Institute Launch the Critical Path for Parkinson’s (CPP) Consortium

October 14, 2015 Parkinson’s UK and Critical Path Institute Launch the Critical Path for Parkinson’s (CPP) Consortium Data from past Parkinson’s trials will be collected, standardized, and integrated, in order to inform new approaches to designing clinical trials focused on early-stage Parkinson’s. London and Tucson – October 14, 2015 – Parkinson’s UK, one of the […]

1 3 4 5 6 7 9